nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—EGFR—type 2 diabetes mellitus	0.402	1	CbGaD
Afatinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.044	0.221	CbGbCtD
Afatinib—ABCG2—Glyburide—type 2 diabetes mellitus	0.0402	0.202	CbGbCtD
Afatinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0392	0.197	CbGbCtD
Afatinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.0283	0.142	CbGbCtD
Afatinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.0195	0.0979	CbGbCtD
Afatinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.0145	0.0729	CbGbCtD
Afatinib—ABCB1—Losartan—type 2 diabetes mellitus	0.0133	0.0667	CbGbCtD
Afatinib—ERBB2—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.00222	1	CbGdCrCtD
Afatinib—IRAK1—islet of Langerhans—type 2 diabetes mellitus	0.00189	0.0417	CbGeAlD
Afatinib—ERBB4—cardiovascular system—type 2 diabetes mellitus	0.00183	0.0404	CbGeAlD
Afatinib—ERBB2—cardiovascular system—type 2 diabetes mellitus	0.00183	0.0404	CbGeAlD
Afatinib—PHKG2—adipose tissue—type 2 diabetes mellitus	0.00179	0.0396	CbGeAlD
Afatinib—ERBB2—kidney—type 2 diabetes mellitus	0.00179	0.0395	CbGeAlD
Afatinib—ERBB2—pancreas—type 2 diabetes mellitus	0.00178	0.0392	CbGeAlD
Afatinib—DYRK1A—cardiovascular system—type 2 diabetes mellitus	0.00176	0.0389	CbGeAlD
Afatinib—ERBB4—cortex of kidney—type 2 diabetes mellitus	0.00174	0.0385	CbGeAlD
Afatinib—DYRK1A—kidney—type 2 diabetes mellitus	0.00172	0.038	CbGeAlD
Afatinib—ERBB2—adipose tissue—type 2 diabetes mellitus	0.00161	0.0356	CbGeAlD
Afatinib—ERBB4—adipose tissue—type 2 diabetes mellitus	0.00161	0.0356	CbGeAlD
Afatinib—DYRK1A—adipose tissue—type 2 diabetes mellitus	0.00155	0.0343	CbGeAlD
Afatinib—IRAK1—nephron tubule—type 2 diabetes mellitus	0.00152	0.0336	CbGeAlD
Afatinib—EGFR—adipose tissue—type 2 diabetes mellitus	0.00137	0.0302	CbGeAlD
Afatinib—IRAK1—pancreas—type 2 diabetes mellitus	0.00133	0.0293	CbGeAlD
Afatinib—IRAK1—cortex of kidney—type 2 diabetes mellitus	0.0013	0.0288	CbGeAlD
Afatinib—PHKG2—liver—type 2 diabetes mellitus	0.00126	0.0278	CbGeAlD
Afatinib—IRAK1—adipose tissue—type 2 diabetes mellitus	0.00121	0.0266	CbGeAlD
Afatinib—LCK—adipose tissue—type 2 diabetes mellitus	0.00118	0.026	CbGeAlD
Afatinib—Vandetanib—SRC—type 2 diabetes mellitus	0.00114	0.25	CrCbGaD
Afatinib—ERBB2—liver—type 2 diabetes mellitus	0.00113	0.025	CbGeAlD
Afatinib—DYRK1A—liver—type 2 diabetes mellitus	0.00109	0.024	CbGeAlD
Afatinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.00106	0.0234	CbGeAlD
Afatinib—EGFR—liver—type 2 diabetes mellitus	0.000959	0.0212	CbGeAlD
Afatinib—ABL1—retina—type 2 diabetes mellitus	0.000906	0.02	CbGeAlD
Afatinib—Vandetanib—VEGFA—type 2 diabetes mellitus	0.000904	0.199	CrCbGaD
Afatinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000854	0.0188	CbGeAlD
Afatinib—IRAK1—liver—type 2 diabetes mellitus	0.000847	0.0187	CbGeAlD
Afatinib—LCK—liver—type 2 diabetes mellitus	0.000826	0.0182	CbGeAlD
Afatinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000767	0.0169	CbGeAlD
Afatinib—Vandetanib—EGFR—type 2 diabetes mellitus	0.000763	0.168	CrCbGaD
Afatinib—ABL1—kidney—type 2 diabetes mellitus	0.00075	0.0165	CbGeAlD
Afatinib—ABL1—pancreas—type 2 diabetes mellitus	0.000745	0.0164	CbGeAlD
Afatinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000731	0.0161	CbGeAlD
Afatinib—Gefitinib—EGFR—type 2 diabetes mellitus	0.000725	0.16	CrCbGaD
Afatinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000676	0.0149	CbGeAlD
Afatinib—ABCG2—nephron tubule—type 2 diabetes mellitus	0.000538	0.0119	CbGeAlD
Afatinib—ABL1—liver—type 2 diabetes mellitus	0.000474	0.0105	CbGeAlD
Afatinib—ABCG2—adipose tissue—type 2 diabetes mellitus	0.000426	0.0094	CbGeAlD
Afatinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	0.00033	0.00727	CbGeAlD
Afatinib—ABCG2—liver—type 2 diabetes mellitus	0.000299	0.0066	CbGeAlD
Afatinib—Mental disorder—Orlistat—type 2 diabetes mellitus	0.000298	0.00178	CcSEcCtD
Afatinib—Malnutrition—Orlistat—type 2 diabetes mellitus	0.000296	0.00176	CcSEcCtD
Afatinib—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000296	0.00176	CcSEcCtD
Afatinib—Rash—Repaglinide—type 2 diabetes mellitus	0.000294	0.00175	CcSEcCtD
Afatinib—Dysgeusia—Valsartan—type 2 diabetes mellitus	0.000294	0.00175	CcSEcCtD
Afatinib—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.000294	0.00175	CcSEcCtD
Afatinib—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.000294	0.00175	CcSEcCtD
Afatinib—Eye disorder—Metformin—type 2 diabetes mellitus	0.000293	0.00175	CcSEcCtD
Afatinib—Epistaxis—Losartan—type 2 diabetes mellitus	0.000293	0.00174	CcSEcCtD
Afatinib—Urinary tract disorder—Irbesartan—type 2 diabetes mellitus	0.000293	0.00174	CcSEcCtD
Afatinib—Headache—Repaglinide—type 2 diabetes mellitus	0.000292	0.00174	CcSEcCtD
Afatinib—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000291	0.00173	CcSEcCtD
Afatinib—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000291	0.00173	CcSEcCtD
Afatinib—Connective tissue disorder—Irbesartan—type 2 diabetes mellitus	0.000291	0.00173	CcSEcCtD
Afatinib—Urethral disorder—Irbesartan—type 2 diabetes mellitus	0.00029	0.00173	CcSEcCtD
Afatinib—Dysgeusia—Orlistat—type 2 diabetes mellitus	0.00029	0.00173	CcSEcCtD
Afatinib—Back pain—Valsartan—type 2 diabetes mellitus	0.00029	0.00173	CcSEcCtD
Afatinib—Dyspnoea—Bromocriptine—type 2 diabetes mellitus	0.000289	0.00172	CcSEcCtD
Afatinib—Muscle spasms—Valsartan—type 2 diabetes mellitus	0.000288	0.00172	CcSEcCtD
Afatinib—Back pain—Orlistat—type 2 diabetes mellitus	0.000287	0.00171	CcSEcCtD
Afatinib—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000286	0.0017	CcSEcCtD
Afatinib—Muscle spasms—Orlistat—type 2 diabetes mellitus	0.000285	0.0017	CcSEcCtD
Afatinib—Cough—Gliclazide—type 2 diabetes mellitus	0.000285	0.0017	CcSEcCtD
Afatinib—Mediastinal disorder—Metformin—type 2 diabetes mellitus	0.000283	0.00168	CcSEcCtD
Afatinib—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000282	0.00168	CcSEcCtD
Afatinib—ABCB1—retina—type 2 diabetes mellitus	0.000282	0.00622	CbGeAlD
Afatinib—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.00028	0.00167	CcSEcCtD
Afatinib—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.00028	0.00167	CcSEcCtD
Afatinib—Vandetanib—CYP3A4—type 2 diabetes mellitus	0.000279	0.0613	CrCbGaD
Afatinib—Rash—Rosiglitazone—type 2 diabetes mellitus	0.000278	0.00165	CcSEcCtD
Afatinib—Constipation—Bromocriptine—type 2 diabetes mellitus	0.000278	0.00165	CcSEcCtD
Afatinib—Upper respiratory tract infection—Ramipril—type 2 diabetes mellitus	0.000278	0.00165	CcSEcCtD
Afatinib—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.000278	0.00165	CcSEcCtD
Afatinib—Nausea—Repaglinide—type 2 diabetes mellitus	0.000277	0.00165	CcSEcCtD
Afatinib—Asthenia—Glipizide—type 2 diabetes mellitus	0.000277	0.00165	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000276	0.00164	CcSEcCtD
Afatinib—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000276	0.00164	CcSEcCtD
Afatinib—Malnutrition—Metformin—type 2 diabetes mellitus	0.000273	0.00163	CcSEcCtD
Afatinib—Pruritus—Glipizide—type 2 diabetes mellitus	0.000273	0.00162	CcSEcCtD
Afatinib—Dysgeusia—Metformin—type 2 diabetes mellitus	0.000268	0.00159	CcSEcCtD
Afatinib—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.000267	0.00159	CcSEcCtD
Afatinib—ABCB1—nephron tubule—type 2 diabetes mellitus	0.000265	0.00586	CbGeAlD
Afatinib—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000265	0.00158	CcSEcCtD
Afatinib—Gefitinib—CYP3A4—type 2 diabetes mellitus	0.000265	0.0583	CrCbGaD
Afatinib—Infection—Gliclazide—type 2 diabetes mellitus	0.000265	0.00158	CcSEcCtD
Afatinib—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000265	0.00157	CcSEcCtD
Afatinib—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000264	0.00157	CcSEcCtD
Afatinib—Muscle spasms—Metformin—type 2 diabetes mellitus	0.000263	0.00156	CcSEcCtD
Afatinib—Cough—Valsartan—type 2 diabetes mellitus	0.000262	0.00156	CcSEcCtD
Afatinib—Renal failure—Ramipril—type 2 diabetes mellitus	0.000262	0.00156	CcSEcCtD
Afatinib—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000262	0.00156	CcSEcCtD
Afatinib—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000261	0.00156	CcSEcCtD
Afatinib—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000261	0.00156	CcSEcCtD
Afatinib—Stomatitis—Ramipril—type 2 diabetes mellitus	0.00026	0.00154	CcSEcCtD
Afatinib—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000259	0.00154	CcSEcCtD
Afatinib—Urinary tract infection—Ramipril—type 2 diabetes mellitus	0.000259	0.00154	CcSEcCtD
Afatinib—Conjunctivitis—Ramipril—type 2 diabetes mellitus	0.000259	0.00154	CcSEcCtD
Afatinib—Cough—Orlistat—type 2 diabetes mellitus	0.000259	0.00154	CcSEcCtD
Afatinib—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000258	0.00154	CcSEcCtD
Afatinib—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000258	0.00154	CcSEcCtD
Afatinib—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000258	0.00153	CcSEcCtD
Afatinib—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000257	0.00153	CcSEcCtD
Afatinib—Body temperature increased—Bromocriptine—type 2 diabetes mellitus	0.000257	0.00153	CcSEcCtD
Afatinib—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000256	0.00153	CcSEcCtD
Afatinib—Dizziness—Glipizide—type 2 diabetes mellitus	0.000255	0.00152	CcSEcCtD
Afatinib—Pruritus—Glimepiride—type 2 diabetes mellitus	0.000255	0.00152	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000254	0.00151	CcSEcCtD
Afatinib—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000253	0.0015	CcSEcCtD
Afatinib—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000252	0.0015	CcSEcCtD
Afatinib—Hepatobiliary disease—Ramipril—type 2 diabetes mellitus	0.000252	0.0015	CcSEcCtD
Afatinib—Epistaxis—Ramipril—type 2 diabetes mellitus	0.000251	0.00149	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.000251	0.00149	CcSEcCtD
Afatinib—Muscle spasms—Irbesartan—type 2 diabetes mellitus	0.000248	0.00148	CcSEcCtD
Afatinib—Alopecia—Losartan—type 2 diabetes mellitus	0.000246	0.00147	CcSEcCtD
Afatinib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000246	0.00147	CcSEcCtD
Afatinib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000245	0.00146	CcSEcCtD
Afatinib—Vomiting—Glipizide—type 2 diabetes mellitus	0.000245	0.00146	CcSEcCtD
Afatinib—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000244	0.00145	CcSEcCtD
Afatinib—Infection—Valsartan—type 2 diabetes mellitus	0.000243	0.00145	CcSEcCtD
Afatinib—Rash—Glipizide—type 2 diabetes mellitus	0.000243	0.00145	CcSEcCtD
Afatinib—Vandetanib—ALB—type 2 diabetes mellitus	0.000243	0.0535	CrCbGaD
Afatinib—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000243	0.00145	CcSEcCtD
Afatinib—Headache—Glipizide—type 2 diabetes mellitus	0.000242	0.00144	CcSEcCtD
Afatinib—Insomnia—Gliclazide—type 2 diabetes mellitus	0.000241	0.00143	CcSEcCtD
Afatinib—Infection—Orlistat—type 2 diabetes mellitus	0.00024	0.00143	CcSEcCtD
Afatinib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.00024	0.00143	CcSEcCtD
Afatinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	0.000238	0.00526	CbGeAlD
Afatinib—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000238	0.00142	CcSEcCtD
Afatinib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000238	0.00142	CcSEcCtD
Afatinib—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000238	0.00141	CcSEcCtD
Afatinib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000238	0.00141	CcSEcCtD
Afatinib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000237	0.00141	CcSEcCtD
Afatinib—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000237	0.00141	CcSEcCtD
Afatinib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000235	0.0014	CcSEcCtD
Afatinib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000235	0.0014	CcSEcCtD
Afatinib—Back pain—Losartan—type 2 diabetes mellitus	0.000235	0.0014	CcSEcCtD
Afatinib—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000235	0.0014	CcSEcCtD
Afatinib—Muscle spasms—Losartan—type 2 diabetes mellitus	0.000233	0.00139	CcSEcCtD
Afatinib—ABCB1—kidney—type 2 diabetes mellitus	0.000233	0.00515	CbGeAlD
Afatinib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000233	0.00139	CcSEcCtD
Afatinib—ABCB1—pancreas—type 2 diabetes mellitus	0.000232	0.00511	CbGeAlD
Afatinib—Headache—Pioglitazone—type 2 diabetes mellitus	0.000231	0.00138	CcSEcCtD
Afatinib—Gefitinib—ALB—type 2 diabetes mellitus	0.000231	0.0508	CrCbGaD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000231	0.00137	CcSEcCtD
Afatinib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.00023	0.00137	CcSEcCtD
Afatinib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00023	0.00137	CcSEcCtD
Afatinib—Nausea—Glipizide—type 2 diabetes mellitus	0.000229	0.00136	CcSEcCtD
Afatinib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000229	0.00136	CcSEcCtD
Afatinib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000228	0.00136	CcSEcCtD
Afatinib—Constipation—Gliclazide—type 2 diabetes mellitus	0.000228	0.00136	CcSEcCtD
Afatinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	0.000227	0.00501	CbGeAlD
Afatinib—Rash—Glimepiride—type 2 diabetes mellitus	0.000227	0.00135	CcSEcCtD
Afatinib—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000227	0.00135	CcSEcCtD
Afatinib—Rash—Sitagliptin—type 2 diabetes mellitus	0.000226	0.00135	CcSEcCtD
Afatinib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000226	0.00135	CcSEcCtD
Afatinib—Headache—Glimepiride—type 2 diabetes mellitus	0.000225	0.00134	CcSEcCtD
Afatinib—Cough—Irbesartan—type 2 diabetes mellitus	0.000225	0.00134	CcSEcCtD
Afatinib—Headache—Sitagliptin—type 2 diabetes mellitus	0.000225	0.00134	CcSEcCtD
Afatinib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000222	0.00132	CcSEcCtD
Afatinib—Infection—Metformin—type 2 diabetes mellitus	0.000222	0.00132	CcSEcCtD
Afatinib—Insomnia—Valsartan—type 2 diabetes mellitus	0.000221	0.00132	CcSEcCtD
Afatinib—Insomnia—Orlistat—type 2 diabetes mellitus	0.000219	0.0013	CcSEcCtD
Afatinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000219	0.0013	CcSEcCtD
Afatinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.000218	0.0013	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000218	0.0013	CcSEcCtD
Afatinib—Skin disorder—Metformin—type 2 diabetes mellitus	0.000217	0.00129	CcSEcCtD
Afatinib—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000216	0.00128	CcSEcCtD
Afatinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000215	0.00128	CcSEcCtD
Afatinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000215	0.00128	CcSEcCtD
Afatinib—Nausea—Glimepiride—type 2 diabetes mellitus	0.000214	0.00127	CcSEcCtD
Afatinib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000213	0.00127	CcSEcCtD
Afatinib—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000213	0.00127	CcSEcCtD
Afatinib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000213	0.00127	CcSEcCtD
Afatinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000213	0.00127	CcSEcCtD
Afatinib—Cough—Losartan—type 2 diabetes mellitus	0.000212	0.00126	CcSEcCtD
Afatinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000211	0.00126	CcSEcCtD
Afatinib—Alopecia—Ramipril—type 2 diabetes mellitus	0.000211	0.00126	CcSEcCtD
Afatinib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000211	0.00126	CcSEcCtD
Afatinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000211	0.00125	CcSEcCtD
Afatinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.00021	0.00125	CcSEcCtD
Afatinib—ABCB1—adipose tissue—type 2 diabetes mellitus	0.00021	0.00464	CbGeAlD
Afatinib—Pruritus—Glyburide—type 2 diabetes mellitus	0.00021	0.00125	CcSEcCtD
Afatinib—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000209	0.00125	CcSEcCtD
Afatinib—Constipation—Valsartan—type 2 diabetes mellitus	0.000209	0.00125	CcSEcCtD
Afatinib—Infection—Irbesartan—type 2 diabetes mellitus	0.000209	0.00124	CcSEcCtD
Afatinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000209	0.00124	CcSEcCtD
Afatinib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000209	0.00124	CcSEcCtD
Afatinib—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000208	0.00124	CcSEcCtD
Afatinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000206	0.00123	CcSEcCtD
Afatinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000206	0.00123	CcSEcCtD
Afatinib—Rash—Bromocriptine—type 2 diabetes mellitus	0.000205	0.00122	CcSEcCtD
Afatinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000205	0.00122	CcSEcCtD
Afatinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000204	0.00122	CcSEcCtD
Afatinib—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000204	0.00121	CcSEcCtD
Afatinib—Headache—Bromocriptine—type 2 diabetes mellitus	0.000203	0.00121	CcSEcCtD
Afatinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000203	0.00121	CcSEcCtD
Afatinib—Muscle spasms—Ramipril—type 2 diabetes mellitus	0.0002	0.00119	CcSEcCtD
Afatinib—Dyspnoea—Metformin—type 2 diabetes mellitus	0.000199	0.00118	CcSEcCtD
Afatinib—Infection—Losartan—type 2 diabetes mellitus	0.000197	0.00117	CcSEcCtD
Afatinib—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000196	0.00117	CcSEcCtD
Afatinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000194	0.00116	CcSEcCtD
Afatinib—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000194	0.00115	CcSEcCtD
Afatinib—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000193	0.00115	CcSEcCtD
Afatinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000193	0.00115	CcSEcCtD
Afatinib—Fatigue—Metformin—type 2 diabetes mellitus	0.000192	0.00114	CcSEcCtD
Afatinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000191	0.00114	CcSEcCtD
Afatinib—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000191	0.00114	CcSEcCtD
Afatinib—Constipation—Metformin—type 2 diabetes mellitus	0.000191	0.00113	CcSEcCtD
Afatinib—Vomiting—Glyburide—type 2 diabetes mellitus	0.000189	0.00112	CcSEcCtD
Afatinib—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000189	0.00112	CcSEcCtD
Afatinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000188	0.00112	CcSEcCtD
Afatinib—Rash—Glyburide—type 2 diabetes mellitus	0.000187	0.00111	CcSEcCtD
Afatinib—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000187	0.00111	CcSEcCtD
Afatinib—Headache—Glyburide—type 2 diabetes mellitus	0.000186	0.00111	CcSEcCtD
Afatinib—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000185	0.0011	CcSEcCtD
Afatinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000183	0.00109	CcSEcCtD
Afatinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000182	0.00109	CcSEcCtD
Afatinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000182	0.00108	CcSEcCtD
Afatinib—Cough—Ramipril—type 2 diabetes mellitus	0.000182	0.00108	CcSEcCtD
Afatinib—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000181	0.00108	CcSEcCtD
Afatinib—Constipation—Irbesartan—type 2 diabetes mellitus	0.00018	0.00107	CcSEcCtD
Afatinib—Insomnia—Losartan—type 2 diabetes mellitus	0.000179	0.00107	CcSEcCtD
Afatinib—Dyspnoea—Losartan—type 2 diabetes mellitus	0.000177	0.00105	CcSEcCtD
Afatinib—Nausea—Glyburide—type 2 diabetes mellitus	0.000176	0.00105	CcSEcCtD
Afatinib—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000176	0.00105	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000176	0.00105	CcSEcCtD
Afatinib—Asthenia—Valsartan—type 2 diabetes mellitus	0.000176	0.00105	CcSEcCtD
Afatinib—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000174	0.00104	CcSEcCtD
Afatinib—Asthenia—Orlistat—type 2 diabetes mellitus	0.000174	0.00103	CcSEcCtD
Afatinib—Pruritus—Valsartan—type 2 diabetes mellitus	0.000173	0.00103	CcSEcCtD
Afatinib—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000172	0.00102	CcSEcCtD
Afatinib—Pruritus—Orlistat—type 2 diabetes mellitus	0.000171	0.00102	CcSEcCtD
Afatinib—Fatigue—Losartan—type 2 diabetes mellitus	0.000171	0.00102	CcSEcCtD
Afatinib—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000169	0.00101	CcSEcCtD
Afatinib—Constipation—Losartan—type 2 diabetes mellitus	0.000169	0.00101	CcSEcCtD
Afatinib—Rash—Gliclazide—type 2 diabetes mellitus	0.000168	0.001	CcSEcCtD
Afatinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.000168	0.000999	CcSEcCtD
Afatinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.000168	0.000997	CcSEcCtD
Afatinib—Headache—Gliclazide—type 2 diabetes mellitus	0.000167	0.000994	CcSEcCtD
Afatinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000167	0.000991	CcSEcCtD
Afatinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	0.000166	0.00099	CcSEcCtD
Afatinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000166	0.000985	CcSEcCtD
Afatinib—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000165	0.000982	CcSEcCtD
Afatinib—Dizziness—Valsartan—type 2 diabetes mellitus	0.000162	0.000964	CcSEcCtD
Afatinib—Dizziness—Orlistat—type 2 diabetes mellitus	0.00016	0.000952	CcSEcCtD
Afatinib—Asthenia—Metformin—type 2 diabetes mellitus	0.00016	0.000952	CcSEcCtD
Afatinib—Nausea—Gliclazide—type 2 diabetes mellitus	0.000158	0.000942	CcSEcCtD
Afatinib—Pruritus—Metformin—type 2 diabetes mellitus	0.000158	0.000939	CcSEcCtD
Afatinib—Body temperature increased—Losartan—type 2 diabetes mellitus	0.000157	0.000932	CcSEcCtD
Afatinib—Vomiting—Valsartan—type 2 diabetes mellitus	0.000156	0.000927	CcSEcCtD
Afatinib—Rash—Valsartan—type 2 diabetes mellitus	0.000154	0.000919	CcSEcCtD
Afatinib—Dermatitis—Valsartan—type 2 diabetes mellitus	0.000154	0.000918	CcSEcCtD
Afatinib—Vomiting—Orlistat—type 2 diabetes mellitus	0.000154	0.000916	CcSEcCtD
Afatinib—Insomnia—Ramipril—type 2 diabetes mellitus	0.000154	0.000914	CcSEcCtD
Afatinib—Headache—Valsartan—type 2 diabetes mellitus	0.000153	0.000913	CcSEcCtD
Afatinib—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000153	0.000908	CcSEcCtD
Afatinib—Rash—Orlistat—type 2 diabetes mellitus	0.000153	0.000908	CcSEcCtD
Afatinib—Dermatitis—Orlistat—type 2 diabetes mellitus	0.000152	0.000907	CcSEcCtD
Afatinib—Headache—Orlistat—type 2 diabetes mellitus	0.000152	0.000902	CcSEcCtD
Afatinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	0.000151	0.000901	CcSEcCtD
Afatinib—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000151	0.000899	CcSEcCtD
Afatinib—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000149	0.00089	CcSEcCtD
Afatinib—Pruritus—Irbesartan—type 2 diabetes mellitus	0.000149	0.000886	CcSEcCtD
Afatinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000148	0.000879	CcSEcCtD
Afatinib—Dizziness—Metformin—type 2 diabetes mellitus	0.000147	0.000878	CcSEcCtD
Afatinib—ABCB1—liver—type 2 diabetes mellitus	0.000147	0.00325	CbGeAlD
Afatinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000147	0.000873	CcSEcCtD
Afatinib—Fatigue—Ramipril—type 2 diabetes mellitus	0.000146	0.000871	CcSEcCtD
Afatinib—Nausea—Valsartan—type 2 diabetes mellitus	0.000145	0.000866	CcSEcCtD
Afatinib—Constipation—Ramipril—type 2 diabetes mellitus	0.000145	0.000864	CcSEcCtD
Afatinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000144	0.000857	CcSEcCtD
Afatinib—Nausea—Orlistat—type 2 diabetes mellitus	0.000144	0.000855	CcSEcCtD
Afatinib—Asthenia—Losartan—type 2 diabetes mellitus	0.000142	0.000846	CcSEcCtD
Afatinib—Vomiting—Metformin—type 2 diabetes mellitus	0.000142	0.000844	CcSEcCtD
Afatinib—Rash—Metformin—type 2 diabetes mellitus	0.000141	0.000837	CcSEcCtD
Afatinib—Dermatitis—Metformin—type 2 diabetes mellitus	0.00014	0.000836	CcSEcCtD
Afatinib—Pruritus—Losartan—type 2 diabetes mellitus	0.00014	0.000834	CcSEcCtD
Afatinib—Headache—Metformin—type 2 diabetes mellitus	0.00014	0.000831	CcSEcCtD
Afatinib—Dizziness—Irbesartan—type 2 diabetes mellitus	0.000139	0.000828	CcSEcCtD
Afatinib—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000135	0.000806	CcSEcCtD
Afatinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	0.000134	0.000799	CcSEcCtD
Afatinib—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000134	0.000796	CcSEcCtD
Afatinib—Rash—Irbesartan—type 2 diabetes mellitus	0.000133	0.00079	CcSEcCtD
Afatinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.000133	0.000789	CcSEcCtD
Afatinib—Nausea—Metformin—type 2 diabetes mellitus	0.000132	0.000788	CcSEcCtD
Afatinib—Headache—Irbesartan—type 2 diabetes mellitus	0.000132	0.000785	CcSEcCtD
Afatinib—Dizziness—Losartan—type 2 diabetes mellitus	0.000131	0.000779	CcSEcCtD
Afatinib—Vomiting—Losartan—type 2 diabetes mellitus	0.000126	0.000749	CcSEcCtD
Afatinib—Nausea—Irbesartan—type 2 diabetes mellitus	0.000125	0.000744	CcSEcCtD
Afatinib—Rash—Losartan—type 2 diabetes mellitus	0.000125	0.000743	CcSEcCtD
Afatinib—Dermatitis—Losartan—type 2 diabetes mellitus	0.000125	0.000742	CcSEcCtD
Afatinib—Headache—Losartan—type 2 diabetes mellitus	0.000124	0.000738	CcSEcCtD
Afatinib—Asthenia—Ramipril—type 2 diabetes mellitus	0.000122	0.000725	CcSEcCtD
Afatinib—Pruritus—Ramipril—type 2 diabetes mellitus	0.00012	0.000715	CcSEcCtD
Afatinib—Nausea—Losartan—type 2 diabetes mellitus	0.000118	0.0007	CcSEcCtD
Afatinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000116	0.000692	CcSEcCtD
Afatinib—Dizziness—Ramipril—type 2 diabetes mellitus	0.000112	0.000668	CcSEcCtD
Afatinib—Vomiting—Ramipril—type 2 diabetes mellitus	0.000108	0.000643	CcSEcCtD
Afatinib—Rash—Ramipril—type 2 diabetes mellitus	0.000107	0.000637	CcSEcCtD
Afatinib—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000107	0.000637	CcSEcCtD
Afatinib—Headache—Ramipril—type 2 diabetes mellitus	0.000106	0.000633	CcSEcCtD
Afatinib—Nausea—Ramipril—type 2 diabetes mellitus	0.000101	0.0006	CcSEcCtD
Afatinib—IRAK1—Immune System—SRC—type 2 diabetes mellitus	5.63e-06	3.15e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.63e-06	3.15e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—INS—type 2 diabetes mellitus	5.61e-06	3.14e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT2—type 2 diabetes mellitus	5.61e-06	3.14e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—RELA—type 2 diabetes mellitus	5.61e-06	3.13e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	5.6e-06	3.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—APOA1—type 2 diabetes mellitus	5.6e-06	3.13e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IRS1—type 2 diabetes mellitus	5.6e-06	3.13e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	5.57e-06	3.11e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CD36—type 2 diabetes mellitus	5.56e-06	3.11e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GNB3—type 2 diabetes mellitus	5.55e-06	3.1e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.52e-06	3.09e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—CASP8—type 2 diabetes mellitus	5.51e-06	3.08e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPP2CA—type 2 diabetes mellitus	5.49e-06	3.07e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOB—type 2 diabetes mellitus	5.49e-06	3.07e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AVP—type 2 diabetes mellitus	5.47e-06	3.06e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP3—type 2 diabetes mellitus	5.47e-06	3.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.47e-06	3.05e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.46e-06	3.05e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—EGFR—type 2 diabetes mellitus	5.46e-06	3.05e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF2—type 2 diabetes mellitus	5.45e-06	3.04e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A2—type 2 diabetes mellitus	5.43e-06	3.03e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.43e-06	3.03e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.43e-06	3.03e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	5.43e-06	3.03e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT2—type 2 diabetes mellitus	5.41e-06	3.02e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.41e-06	3.02e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.4e-06	3.02e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IRS1—type 2 diabetes mellitus	5.39e-06	3.01e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.38e-06	3.01e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—INS—type 2 diabetes mellitus	5.36e-06	2.99e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—AKT1—type 2 diabetes mellitus	5.33e-06	2.97e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.32e-06	2.97e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CPT1A—type 2 diabetes mellitus	5.32e-06	2.97e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTR—type 2 diabetes mellitus	5.32e-06	2.97e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOB—type 2 diabetes mellitus	5.29e-06	2.96e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—type 2 diabetes mellitus	5.27e-06	2.94e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1R—type 2 diabetes mellitus	5.27e-06	2.94e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—type 2 diabetes mellitus	5.25e-06	2.93e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—EGFR—type 2 diabetes mellitus	5.25e-06	2.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LPL—type 2 diabetes mellitus	5.24e-06	2.93e-05	CbGpPWpGaD
Afatinib—ABL1—Hemostasis—AKT1—type 2 diabetes mellitus	5.22e-06	2.92e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NAMPT—type 2 diabetes mellitus	5.22e-06	2.92e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EDN1—type 2 diabetes mellitus	5.21e-06	2.91e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—LIPC—type 2 diabetes mellitus	5.19e-06	2.9e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HBA1—type 2 diabetes mellitus	5.19e-06	2.9e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GCK—type 2 diabetes mellitus	5.19e-06	2.9e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT2—type 2 diabetes mellitus	5.18e-06	2.89e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARA—type 2 diabetes mellitus	5.17e-06	2.89e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—type 2 diabetes mellitus	5.17e-06	2.89e-05	CbGpPWpGaD
Afatinib—LCK—Disease—INS—type 2 diabetes mellitus	5.17e-06	2.89e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.16e-06	2.88e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP11A1—type 2 diabetes mellitus	5.15e-06	2.88e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADCY5—type 2 diabetes mellitus	5.13e-06	2.87e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—type 2 diabetes mellitus	5.1e-06	2.85e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3R1—type 2 diabetes mellitus	5.09e-06	2.84e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC9A1—type 2 diabetes mellitus	5.06e-06	2.83e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LPL—type 2 diabetes mellitus	5.05e-06	2.82e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—SRC—type 2 diabetes mellitus	5.04e-06	2.81e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AGT—type 2 diabetes mellitus	5.01e-06	2.8e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CETP—type 2 diabetes mellitus	5e-06	2.8e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT2—type 2 diabetes mellitus	4.99e-06	2.79e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—type 2 diabetes mellitus	4.97e-06	2.78e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—SRC—type 2 diabetes mellitus	4.96e-06	2.77e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADCY5—type 2 diabetes mellitus	4.95e-06	2.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—EGFR—type 2 diabetes mellitus	4.94e-06	2.76e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—type 2 diabetes mellitus	4.93e-06	2.76e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SERPINE1—type 2 diabetes mellitus	4.92e-06	2.75e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CALM1—type 2 diabetes mellitus	4.92e-06	2.75e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NOS3—type 2 diabetes mellitus	4.92e-06	2.75e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	4.92e-06	2.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.92e-06	2.75e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—type 2 diabetes mellitus	4.91e-06	2.74e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3R1—type 2 diabetes mellitus	4.91e-06	2.74e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—type 2 diabetes mellitus	4.91e-06	2.74e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.91e-06	2.74e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—BCL2—type 2 diabetes mellitus	4.9e-06	2.74e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOA1—type 2 diabetes mellitus	4.85e-06	2.71e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—type 2 diabetes mellitus	4.85e-06	2.71e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—AKT1—type 2 diabetes mellitus	4.84e-06	2.7e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.83e-06	2.7e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.83e-06	2.7e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—RELA—type 2 diabetes mellitus	4.79e-06	2.68e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—type 2 diabetes mellitus	4.77e-06	2.67e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—AKT1—type 2 diabetes mellitus	4.77e-06	2.66e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SERPINE1—type 2 diabetes mellitus	4.75e-06	2.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	4.74e-06	2.65e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—NFKB1—type 2 diabetes mellitus	4.73e-06	2.64e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—BCL2—type 2 diabetes mellitus	4.72e-06	2.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—C3—type 2 diabetes mellitus	4.72e-06	2.64e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—AKT1—type 2 diabetes mellitus	4.7e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3R1—type 2 diabetes mellitus	4.7e-06	2.63e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—NOS3—type 2 diabetes mellitus	4.7e-06	2.63e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCR5—type 2 diabetes mellitus	4.65e-06	2.6e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SREBF1—type 2 diabetes mellitus	4.65e-06	2.6e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PSMD6—type 2 diabetes mellitus	4.65e-06	2.6e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SNAP25—type 2 diabetes mellitus	4.65e-06	2.6e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—RELA—type 2 diabetes mellitus	4.63e-06	2.59e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—RELA—type 2 diabetes mellitus	4.62e-06	2.58e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—AKT1—type 2 diabetes mellitus	4.59e-06	2.56e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CTGF—type 2 diabetes mellitus	4.57e-06	2.55e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—AKT1—type 2 diabetes mellitus	4.55e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—C3—type 2 diabetes mellitus	4.55e-06	2.54e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3R1—type 2 diabetes mellitus	4.53e-06	2.53e-05	CbGpPWpGaD
Afatinib—LCK—Disease—NOS3—type 2 diabetes mellitus	4.53e-06	2.53e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMGCR—type 2 diabetes mellitus	4.52e-06	2.53e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.5e-06	2.52e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.5e-06	2.51e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.49e-06	2.51e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AGT—type 2 diabetes mellitus	4.49e-06	2.51e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—AKT1—type 2 diabetes mellitus	4.47e-06	2.5e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—ALB—type 2 diabetes mellitus	4.44e-06	2.48e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.44e-06	2.48e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADRA2A—type 2 diabetes mellitus	4.43e-06	2.47e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.42e-06	2.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.41e-06	2.46e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—SRC—type 2 diabetes mellitus	4.41e-06	2.46e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—AKT1—type 2 diabetes mellitus	4.4e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—LEP—type 2 diabetes mellitus	4.39e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—type 2 diabetes mellitus	4.39e-06	2.46e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—type 2 diabetes mellitus	4.36e-06	2.43e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.35e-06	2.43e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.34e-06	2.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HIF1A—type 2 diabetes mellitus	4.34e-06	2.42e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS2—type 2 diabetes mellitus	4.33e-06	2.42e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AGT—type 2 diabetes mellitus	4.32e-06	2.41e-05	CbGpPWpGaD
Afatinib—LCK—Hemostasis—AKT1—type 2 diabetes mellitus	4.3e-06	2.4e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—PTGS2—type 2 diabetes mellitus	4.3e-06	2.4e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PPARG—type 2 diabetes mellitus	4.27e-06	2.39e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2E1—type 2 diabetes mellitus	4.25e-06	2.38e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CALM1—type 2 diabetes mellitus	4.25e-06	2.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—type 2 diabetes mellitus	4.23e-06	2.37e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—type 2 diabetes mellitus	4.23e-06	2.37e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1A2—type 2 diabetes mellitus	4.21e-06	2.35e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A1—type 2 diabetes mellitus	4.21e-06	2.35e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—type 2 diabetes mellitus	4.2e-06	2.35e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—INS—type 2 diabetes mellitus	4.19e-06	2.34e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOA1—type 2 diabetes mellitus	4.19e-06	2.34e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.18e-06	2.34e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PRKCB—type 2 diabetes mellitus	4.14e-06	2.32e-05	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—type 2 diabetes mellitus	4.14e-06	2.31e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP3A4—type 2 diabetes mellitus	4.1e-06	2.29e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—NFKB1—type 2 diabetes mellitus	4.04e-06	2.26e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GCG—type 2 diabetes mellitus	4.03e-06	2.25e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A4—type 2 diabetes mellitus	4.03e-06	2.25e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—type 2 diabetes mellitus	4.02e-06	2.25e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PRKCB—type 2 diabetes mellitus	3.99e-06	2.23e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—type 2 diabetes mellitus	3.95e-06	2.21e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.92e-06	2.19e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	3.91e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—NFKB1—type 2 diabetes mellitus	3.9e-06	2.18e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—type 2 diabetes mellitus	3.87e-06	2.16e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—type 2 diabetes mellitus	3.86e-06	2.16e-05	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.86e-06	2.16e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—type 2 diabetes mellitus	3.84e-06	2.15e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—type 2 diabetes mellitus	3.79e-06	2.12e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IRS1—type 2 diabetes mellitus	3.78e-06	2.11e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—type 2 diabetes mellitus	3.77e-06	2.1e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—INS—type 2 diabetes mellitus	3.75e-06	2.1e-05	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—type 2 diabetes mellitus	3.72e-06	2.08e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.69e-06	2.06e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3R1—type 2 diabetes mellitus	3.68e-06	2.05e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—type 2 diabetes mellitus	3.68e-06	2.05e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—type 2 diabetes mellitus	3.64e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.63e-06	2.03e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—type 2 diabetes mellitus	3.63e-06	2.03e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.63e-06	2.03e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—INS—type 2 diabetes mellitus	3.62e-06	2.02e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCL2—type 2 diabetes mellitus	3.56e-06	1.99e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.55e-06	1.98e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—type 2 diabetes mellitus	3.5e-06	1.96e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—type 2 diabetes mellitus	3.5e-06	1.95e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT2—type 2 diabetes mellitus	3.5e-06	1.95e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—type 2 diabetes mellitus	3.48e-06	1.94e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	3.48e-06	1.94e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.48e-06	1.94e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	3.46e-06	1.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.45e-06	1.93e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	3.41e-06	1.91e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—type 2 diabetes mellitus	3.39e-06	1.9e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—type 2 diabetes mellitus	3.36e-06	1.88e-05	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—type 2 diabetes mellitus	3.35e-06	1.87e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—type 2 diabetes mellitus	3.34e-06	1.87e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	3.32e-06	1.86e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	3.31e-06	1.85e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.29e-06	1.84e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.29e-06	1.84e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.26e-06	1.82e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	3.22e-06	1.8e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.19e-06	1.78e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—type 2 diabetes mellitus	3.18e-06	1.78e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	3.17e-06	1.77e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	3.17e-06	1.77e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	3.16e-06	1.77e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.13e-06	1.75e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—type 2 diabetes mellitus	3.11e-06	1.74e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RELA—type 2 diabetes mellitus	3.1e-06	1.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	3.1e-06	1.73e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	3.09e-06	1.72e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.08e-06	1.72e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	3.01e-06	1.68e-05	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—type 2 diabetes mellitus	3e-06	1.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	2.99e-06	1.67e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	2.97e-06	1.66e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	2.97e-06	1.66e-05	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—type 2 diabetes mellitus	2.94e-06	1.64e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	2.85e-06	1.59e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	2.8e-06	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.8e-06	1.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—type 2 diabetes mellitus	2.78e-06	1.55e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	2.74e-06	1.53e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	2.71e-06	1.51e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	2.69e-06	1.5e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	2.66e-06	1.49e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	2.65e-06	1.48e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.64e-06	1.48e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	2.62e-06	1.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.61e-06	1.46e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	2.56e-06	1.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	2.55e-06	1.42e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—type 2 diabetes mellitus	2.54e-06	1.42e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	2.52e-06	1.41e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—type 2 diabetes mellitus	2.45e-06	1.37e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—type 2 diabetes mellitus	2.45e-06	1.37e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—type 2 diabetes mellitus	2.44e-06	1.36e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.37e-06	1.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	2.35e-06	1.31e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—type 2 diabetes mellitus	2.34e-06	1.31e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—type 2 diabetes mellitus	2.34e-06	1.31e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	2.31e-06	1.29e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	2.29e-06	1.28e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	2.27e-06	1.27e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.26e-06	1.26e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—type 2 diabetes mellitus	2.26e-06	1.26e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—type 2 diabetes mellitus	2.26e-06	1.26e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.18e-06	1.22e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—type 2 diabetes mellitus	2.16e-06	1.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	2.1e-06	1.17e-05	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—type 2 diabetes mellitus	2.08e-06	1.16e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	2.08e-06	1.16e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	2.06e-06	1.15e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	1.99e-06	1.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	1.99e-06	1.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	1.82e-06	1.02e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—type 2 diabetes mellitus	1.69e-06	9.44e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—type 2 diabetes mellitus	1.64e-06	9.16e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	1.58e-06	8.83e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.51e-06	8.45e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	1.46e-06	8.15e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	9.14e-07	5.1e-06	CbGpPWpGaD
